Amide cinnamate and cinnamic acid derivatives are compounds that are potentially useful as anti-cancer agents. The purpose of this study is to assess the anti-cancer properties of seven derivatives of amide cinnamate using both in silico and in vitro methods. The study compared the potential anti-cancer activity of the seven derivatives of amide cinnamate and tamoxifen as a positive control. To evaluate the in silico anti-cancer activity, an α-estrogen receptor was used from the protein data bank (ID: 4 WZV). In addition, the in vitro analysis was conducted on the Michigan Cancer Foundation-7 breast cancer cell line. Out of all the cinnamic amide derivatives examined, phenyl amide cinnamate exhibited the strongest anti-cancer activity. This result was confirmed by molecular docking studies that explored the binding interactions between the amide cinnamate derivatives and cancer proteins. The docking score for phenyl amide cinnamate was the highest, followed by p-methoxy phenyl amide cinnamate and octyl amide cinnamate. However, all the cinnamic amide derivatives tested had lower activity than tamoxifen. The results of the docking studies revealed a significant correlation between the ligand-binding mode and the amino acid residues, as indicated by the in vitro bioactivity tests.
Key words: amide cinnamate derivatives, inhibition, MCF-7 cells, molecular docking
|
